CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy
Status:
Completed
Trial end date:
2017-11-07
Target enrollment:
Participant gender:
Summary
Testosterone (T) replacement prevents bone loss and relieves symptoms associated with
androgen deficiency in male patients with hypogonadism, but at the expense of an increase in
prostate-related adverse events and in the hematocrit values above the normal which may lead
to bad circulatory outcomes. Most of the effects of T on the male skeleton are mediated by
its conversion to estradiol (E2) by the enzyme aromatase. Genetic variations in the aromatase
(CYP19A1) gene result in enzymes with variable activity and variable levels of E2 and T. This
project is designed to determine if genetic variations in the CYP19A1 gene will result in
differences in the skeletal response and incidence of side effects from T treatment in
patients with low T. A large number of male Veterans are on T. Results from this project will
help identify patients who would benefit from the therapy from those at risk for side
effects, and would definitely have an impact in the future care of these patients and male
patients in general once genetic profiling becomes part of the standard of care.